Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model

Cancer Gene Therapy

Volumn 19, Issue 8, 2012, Pages 558-565

  Chaves, K C B ^a,b   Peron, J P S ^c   Chammas, R ^c   Turaca L T ^a   Pesquero, J B ^a   Braga, M S ^a,b   Foguer, K ^a,b   Schor, N ^a   Bellini, M H ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

endostatin; ICAM 1; orthotopic metastatic model; RCC; VCAM 1

Indexed keywords

ALPHA2 INTEGRIN; CD34 ANTIGEN; ENDOSTATIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE THERAPY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPHOCYTE SUBPOPULATION; MALE; MEDIASTINUM LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; UPREGULATION;

ANIMALS; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENDOSTATINS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84864129144     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.32     Document Type: Article

References (42)

1. Sacco E, Pinto F, Totaro A, D'Addessi A, Racioppi M, Gulino G et al. Imaging of renal cell carcinoma: state of the art and recent advances. Urol Int 2011; 2: 125-139.
2. Ruys AT, Tanis PJ, Iris ND, van Duijvendijk P, Verhoef C, Porte RJ et al. Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 2011; 7: 1932-1938.
3. Chintalapudi MR, Markiewicz M, Kose N, Dammai V, Champion KJ, Hoda RS et al. Cyr61/CCN1 and CTGF/CCN2 mediate the pro-angiogenic activity of VHL mutant renal carcinoma cells. Carcinogenesis 2008; 4: 696-703. (Pubitemid 351494156)
4. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011; 2: 4-13.
5. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 1: 343-347.
6. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 2010; 12: 95-112.
7. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002; 7: 12-17. (Pubitemid 34620430)
8. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y et al. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 2010; 5: e10715.
9. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008; 15: 2152-2161.
10. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009; 6: 959-971.
11. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69: 8412-8419.
12. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011; 60: 644-661.
13. Kopecky O, Lukesövä S, Vroblovä V, Vokurkovä D, Morä ek P, S afrä ek et al. Phenotype analysis of tumor-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal cell carcinoma. ACTA MEDICA (Hradec Králové) 2007; 50: 207-212.
14. Simonson WTN, Allison KH. Tumour-infiltrating lymphocytes in cancer: implications for the diagnostic pathologist. Diagn Histopathol 2010; 17: 80-90.
15. Kondo T, Nakazawa H, Ito F, Hashimoto Y, OsakaY, Futatsuyama K et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006; 97: 780-786. (Pubitemid 43983791)
16. Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 2004; 10: 6360s-6366s. (Pubitemid 39287492)
17. Kirkwood JM, Tarhini AA. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 2009; 27: 2583-2585.
18. Griffioen AW, Tromp SC, Hillen HF. Angiogenesis modulates the tumour immune response. Int J Exp Pathol 1998; 6: 363-368. (Pubitemid 29010696)
19. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol 2002; 12: 1508-1512.
20. Limaye V, Vadas M. The vascular endothelium: structure and function. In: Fitridge R, Thompson M (eds). Mechanisms of Vascular Disease: A Textbook for Vascular Surgeons. 1st edn. Cambridge University Press: New York, 2007, pp 1-10.
21. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 3: 1071-1121.
22. Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Rügg C. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 2010; 6: 529-545.
23. Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006; 22: 10770-10777. (Pubitemid 44876972)
24. Dirkx AE, Oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 6: 621-630. (Pubitemid 44933306)
25. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 3: 247-251.
26. Cichy MC, Rocha FG, Tristão VR, Pessoa EA, Cenedeze MA, Nürmberg Jr R et al. Collagen XVIII/endostatin expression in experimental endotoxemic acute renal failure. Braz J Med Biol Res 2009; 12: 1150-1155.
27. Yu Y, Moulton KS, Khan MK, Vineberg S, Boye E, Davis VM et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci USA 2004; 101: 8005-8010. (Pubitemid 38698044)
28. Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci USA 2011; 24: 9939-9944.
29. Coutinho EL, Andrade LN, Chammas R, Morganti L, Schor N, Bellini MH. Anti-tumor vector of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma. FASEB J 2007; 12: 3153-3161. (Pubitemid 47569816)
30. Rocha FG, Chaves KC, Chammas R, Peron JP, Rizzo LV, Schor N et al. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. Cancer Immunol Immunother 2010; 9: 1357-1365.
31. de Goe s Rocha FG, Chaves KC, Gomes CZ, Campanharo CB, Courrol LC, Schor N et al. Erythrocyte protoporphyrin fluorescence as a biomarker for monitoring antiangiogenic cancer therapy. J Fluoresc 2010; 6: 1225-1231.
32. Rocha FG, Calvo FB, Chaves KC, Peron JP, Marques RF, de Borba TR. Endostatinand interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma. J Gene Med 2011; 3: 148-157.
33. van Beijnum JR, Rousch M, Castermans K, van der Linden E, Griffioen AW. Isolation of endothelial cells from fresh tissues. Nat Protoc 2008; 6: 1085-1091. (Pubitemid 351818695)
34. Fridman WH, Pagè s F, Sautè s-Fridman C, Galons J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev 2012; 12: 298-306.
35. Sherief HM, Low SH, Miura M, Kudo N, Novick AC, Weimbs T. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as screening assay. J Urol 2003; 169: 1530-1534. (Pubitemid 36323838)
36. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 9: 2322-2329. (Pubitemid 36538644)
37. Blaheta RA, Powerski M, Hudak L, Juengel E, Jonas D, von Knethen A et al. Tumorendothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy. Neoplasia 2009; 10: 1054-1063.
38. Tanabe K, Campbell SC, Alexander JP, Steinbach F, Edinger MG, Tubbs RR et al. Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma. Urol Res 1997; 4: 231-238. (Pubitemid 27374946)
39. Shioi K, Komiya A, Hattori K, Huang Y, Sano F, Murakami T et al. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients. Clin Cancer Res 2006; 24: 7339-7346. (Pubitemid 46095406)
40. White UA, Stephens JM. The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr Pharm Des 2011; 4: 340-346.
41. Linker RA, Luhder F, Kallen KJ, Lee DH, Engelhardt B, Rose-John S et al. IL-6 transsignalling modulates the early effector phase of EAE and targets the bloodbrain barrier. J Neuroimmunol 2008; 1-2: 64-72.
42. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011; 2011: 765624.